BIRIPERONE

Details

Stereochemistry	RACEMIC
Molecular Formula	C24H26FN3O
Molecular Weight	391.4811
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

FC1=CC=C(C=C1)C(=O)CCCN2CCN3CC4=C(CC3C2)C5=C(N4)C=CC=C5

InChI

InChIKey=YCNCIZWAGQTWBI-UHFFFAOYSA-N

InChI=1S/C24H26FN3O/c25-18-9-7-17(8-10-18)24(29)6-3-11-27-12-13-28-16-23-21(14-19(28)15-27)20-4-1-2-5-22(20)26-23/h1-2,4-5,7-10,19,26H,3,6,11-16H2

HIDE SMILES / InChI

Molecular Formula	C24H26FN3O
Molecular Weight	391.4811
Charge	0
Count

Stereochemistry	RACEMIC
Additional Stereochemistry	No
Defined Stereocenters	0 / 1
E/Z Centers	0
Optical Activity	( + / - )

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21206602 | https://www.passeidireto.com/arquivo/22911694/2016-equine-prohibited-substances-list/2

Biriperone (also known as Centbutindole) was developed as an antipsychotic drug. It has shown effective antipsychotic activity in schizophrenic patients. Biriperone acts as a dopamine antagonist, and also as a blocker of 5HT(2) receptor. Clinically the drug has passed through phase I, II & III clinical trials successfully, however, the use of this drug was banned.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Dopamine D2 receptor 311 Target ID: CHEMBL339 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17869521	Antagonist 2849		7.88 null [pKi]
Serotonin 2a (5-HT2a) receptor 237 Target ID: CHEMBL322 Sources: https://www.ncbi.nlm.nih.gov/pubmed/17869521	Antagonist 2849		7.619 null [pKi]

PubMed

Title	Date	PubMed
Pharmacokinetics, in-situ absorption and protein binding studies of a new neuroleptic agent centbutindole in rats.	2003-06	12791412
Metabolism and excretion of centbutindole (neuroleptic) in rats after oral administration.	2002-12	12542891
Comparative efficacy of centbutindole & risperidone in schizophrenia.	2002-10	21206602
Effect of dopamine agonists and antagonists on the lorazepam withdrawal syndrome in rats.	2000-03	10744342

Sample Use Guides

In Vivo Use Guide

Patietns were randomly allocated to receive either 4.5mg of centbutindole or 6 mg of risperidone. The drug was formulated in capsules identical in colour, shape and size. Each capsule contained centbutidole (1.5 mg) or risperidone (2 mg). Initial dose was 1 Capsule twice a day for three days increasing to 1 capsule in the morning and 2 capsule at bed time through out the study period of 8 weeks.

Route of Administration: Oral

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:25:49 GMT 2025` Edited by `admin` on `Mon Mar 31 18:25:49 GMT 2025`
Record UNII	5776HBV7UD
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

BIRIPERONE

Official Name

English

NSC-143691

Preferred Name

English

biriperone [INN]

Common Name

English

(±)-4'-FLUORO-4-(3,4,6,7,12,12A-HEXAHYDROPYRAZINO(1',2':1,6)PYRIDO(3,4-B)INDOL-2(1H)-YL)BUTYROPHENONE

Common Name

English

BIRIPERONE [MART.]

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C28197